We are live on ! Find out more
FFVM

Founders Fund VII Management Portfolio holdings

AUM $2.03M
1-Year Est. Return 72.34%
This Fund
S&P 500
This Quarter Est. Return
+4.3%
1 Year Est. Return
+72.34%
3 Year Est. Return
-64.66%
5 Year Est. Return
-90.66%
10 Year Est. Return
–
AUM
$1.76M
AUM Growth
-$11.1M
Cap. Flow
-$11.2M
Cap. Flow %
-635.74%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
1
Compass Pathways
CMPS
$2.04B
$1.76M 100%
278,880
– –
ABCL icon
2
AbCellera Biologics
ABCL
$3.99B
– –
-3,773,530
Closed -$11.2M

Similar funds

FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return
FFGM
Founders Fund Growth Management San Francisco, California $7.04M AUM 82.06% 1-Year Est. Return

Founders Fund VII Management's Q3 2024 Portfolio in Review

As of Q3 2024, Founders Fund VII Management held 2 positions worth $1.76M, down 86% from $12.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Founders Fund VII Management withdrew a net $11.2M in Q3 2024, closing 1 position. Its most notable exit was AbCellera Biologics, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Founders Fund VII Management fully exited AbCellera Biologics in Q3 2024, selling an estimated $11.2M.
  • Founders Fund VII Management's ten largest holdings make up 100% of its $1.76M portfolio in Q3 2024.
  • Founders Fund VII Management opened 0 new positions and closed 1 in Q3 2024.
  • Founders Fund VII Management's portfolio value fell 86% quarter-over-quarter to $1.76M.

Based on Founders Fund VII Management's 13F filing for Q3 2024, filed 14 Nov 2024.